

13 November 2023

ASX Announcement

Screening commences for ISLA-101 Single Ascending Dose study

MELBOURNE Australia, 13 November 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to announce that screening of subjects for the ISLA-101 Single Ascending Dose study has formally commenced.

ISLA-101 is a well-known drug candidate that is being repurposed for the prevention and treatment of dengue and other mosquito (or vector) borne diseases.

Dengue fever is a viral infection transmitted to humans through the bite of infected mosquitoes, with severe cases leading to serious illness and death. The number of dengue cases reported to the World Health Organisation (WHO) have increased more than eight fold over the last two decades, with one modelling estimate indicating there are now 390 million dengue virus infections per year.¹

The Single Ascending Dose study is a dose escalation study, in which three cohorts of healthy subjects will receive escalating doses of ISLA-101. The aim of the study is to ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus.

Today’s news follows receipt of approval from the Human Research Ethics Committee to commence the study (ASX: 7 November 2023), which is being run at Scientia Clinical Research’s clinical trial facilities in Sydney (NSW) by Contract Research Organisation, Beyond Drug Development.

Island’s CEO and Managing Director, Dr David Foster said: *“Following on from ethics approval and also our recent Site Initiation Visit, we are delighted to now be one step closer to dosing subjects in this study. With subject screening underway, we expect first patient dosing to occur imminently and look forward to keeping investors updated on the progress of this important study.”*

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

¹ <https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue>



Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.